Morgan Keenan Comments on AtriCure

Morgan Keegan has published a report on AtriCure ATRC after a grant to develop minimally invasive surgical technology. In the report, Morgan Keenan comments, "We think AtriCure shares are currently traded near fair value. Using a 10-year DCF and EV/Sales, AtriCure shares appear fairly valued in the range of $14 $15. Based on a 40% weighting of our DCF value and a 60% weighting of our EV/Sales value, we arrive at a blended valuation of $14 which is near the current stock price." Morgan Keenan rated AtriCure a Market Perform with a price target of $14.00. AtriCure closed Friday at $13.62.